Drug intelligence / Profile preview

Xiaozhong Formula

Development stage: Preclinical
Lead developer: Eye Hospital, China Academy of Chinese Medical Sciences
Administration: Oral

Overview

Xiaozhong Formula is a Traditional Chinese Medicine (TCM) formula currently under investigation for the treatment of diabetic macular edema (DME). It is being studied in clinical trials, often in combination with anti-VEGF drugs like Compaccip, to address the complex pathology of DME. While its precise mechanism of action is not fully detailed in the provided context, TCM approaches for macular edema generally aim to reduce intraretinal fluid accumulation and improve visual acuity.

Brand names: xiaozhong granules
Other names: Xiaozhong formula Granule消肿方颗粒

Beyond the preview

Go deeper on Xiaozhong Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaozhong Formula.

Explore the full profile